What type of study is this?

This is a Experimental Study study.

September 27, 2025Cancer Research

Abstract A020-PR004: KAT6A and KAT6B are therapeutic targets to enhance the efficacy of differentiation therapy and GD2 immunotherapy in neuroblastoma

View Full Paper

Ask AI

Bookmark

Authors

Research demonstrates KAT6A and KAT6B as potential targets, improving retinoic acid and GD2 immunotherapy effectiveness in neuroblastoma.

Combination therapy with PF-9363 and retinoic acid significantly suppresses tumor growth beyond treatment withdrawal, enhancing long-term effectiveness.
The study showed a sustained downregulation of MYCN in neuroblastoma cells treated with PF-9363 and retinoic acid, a crucial finding for therapeutic strategies.
In NSG xenograft models, PF-9363 alone greatly reduced tumor volume compared to controls, indicating its strong anti-tumor activity.
The results suggest that targeting KAT6A and KAT6B can optimize differentiation therapy and GD2 immunotherapy in challenging pediatric cancers.

Weichert‐Leahey et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark